Find Reports

Select Report Type

Reimbursement Review

Displaying 151 - 175 of 1422

Please scroll or swipe to the right to view the full content.

Title	Brand Name	Generic Name	Files	Therapeutic Area	Recommendation Type	Status	Submission Date	Recommendation Date Sort ascending	Project Number
caplacizumab	Cablivi	caplacizumab	Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Acquired thrombotic thrombocytopenic purpura (aTTP)	Do not reimburse	Complete	Jun 7, 2022	Apr 5, 2023	SR0736-000
nivolumab	Opdivo	nivolumab	Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Resectable Non-Small Cell Lung Cancer	Reimburse with clinical criteria and/or conditions	Complete	Sep 13, 2022	Mar 30, 2023	PC0303-000
brexucabtagene autoleucel	Tecartus	brexucabtagene autoleucel	Recommendation and Reasons Clinical, Pharmacoeconomic and Ethics combined Report Stakeholder feedback on Draft Recommendation	Acute lymphoblastic leukemia	Reimburse with clinical criteria and/or conditions	Complete	Sep 16, 2022	Mar 29, 2023	PG0304-000
pegcetacoplan	Empaveli	pegcetacoplan	Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Paroxysmal nocturnal hemoglobinuria	Reimburse with clinical criteria and/or conditions	Complete	Aug 26, 2022	Mar 20, 2023	SR0748-000
finerenone	Kerendia	finerenone	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	Chronic kidney disease	Reimburse with clinical criteria and/or conditions	Complete	May 20, 2022	Mar 8, 2023	SR0737-000
lutetium vipivotide tetraxetan	Pluvicto	lutetium vipivotide tetraxetan	Recommendation and Reasons Clinical, Pharmacoeconomic, Ethics, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Metastatic castration-resistant prostate cancer	Reimburse with clinical criteria and/or conditions	Complete	Jul 21, 2022	Mar 3, 2023	PC0297-000
amivantamab	Rybrevant	amivantamab	Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Non-small cell lung cancer	Reimburse with clinical criteria and/or conditions	Complete	Apr 21, 2022	Mar 1, 2023	PC0289-000
olaparib	Lynparza	olaparib	Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	gBRCAm, HER2-negative high-risk early breast cancer	Reimburse with clinical criteria and/or conditions	Complete	Aug 3, 2022	Mar 1, 2023	PC0299-000
ravulizumab	Ultomiris	ravulizumab	Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Atypical hemolytic uremic syndrome	Reimburse with clinical criteria and/or conditions	Complete	Jun 8, 2022	Feb 27, 2023	SR0740-000
berotralstat	Orladeyo	berotralstat	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	hereditary angioedema (HAE)	Reimburse with clinical criteria and/or conditions	Complete	Feb 22, 2022	Feb 17, 2023	SR0723-000
lumasiran	Oxlumo	lumasiran	Recommendation and Reasons Clinical, Pharmacoeconomic and Ethics combined Report Stakeholder feedback on Draft Recommendation	Primary hyperoxaluria type 1	Reimburse with clinical criteria and/or conditions	Complete	May 10, 2022	Feb 8, 2023	SR0734-000
axicabtagene ciloleucel	Yescarta	axicabtagene ciloleucel	Recommendation and Reasons Clinical, Pharmacoeconomic and Ethics combined Report Stakeholder feedback on Draft Recommendation	Diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL)	Reimburse with clinical criteria and/or conditions	Complete	Jun 9, 2022	Feb 3, 2023	PG0293-000
durvalumab	Imfinzi	durvalumab	Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Biliary tract cancer	Reimburse with clinical criteria and/or conditions	Complete	Jul 14, 2022	Feb 3, 2023	PC0296-000
pembrolizumab	Keytruda	pembrolizumab	Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Advanced endometrial cancer	Reimburse with clinical criteria and/or conditions	Complete	Dec 15, 2021	Feb 3, 2023	PC0280-000
anifrolumab	Saphnelo	anifrolumab	Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Systemic lupus erythematosus	Reimburse with clinical criteria and/or conditions	Complete	Jan 28, 2022	Jan 20, 2023	SR0717-000
dupilumab	Dupixent	dupilumab	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	Asthma	Reimburse with clinical criteria and/or conditions	Complete	Jun 28, 2022	Jan 20, 2023	SR0745-000
deferiprone	Ferriprox	deferiprone	Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Transfusional iron overload	Reimburse with clinical criteria and/or conditions	Complete	Jun 8, 2022	Jan 19, 2023	SR0741-000
belimumab	Benlysta	belimumab	Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Lupus nephritis	Reimburse with clinical criteria and/or conditions	Complete	Jul 7, 2022	Jan 19, 2023	SR0746-000
brolucizumab	Beovu	brolucizumab	Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Diabetic macular edema	Reimburse with clinical criteria and/or conditions	Complete	Jun 30, 2022	Jan 18, 2023	SR0747-000
dupilumab	Dupixent	dupilumab	Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	atopic dermatitis	Reimburse with clinical criteria and/or conditions	Complete	Jul 15, 2022	Jan 18, 2023	SF0754-000
lemborexant	Dayvigo	lemborexant	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	Insomnia	Do not reimburse	Complete	Feb 28, 2022	Jan 10, 2023	SR0716-000
pembrolizumab	Keytruda	pembrolizumab	Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Triple-negative breast cancer	Reimburse with clinical criteria and/or conditions	Complete	Jun 20, 2022	Jan 6, 2023	PC0295-000
darolutamide	Nubeqa	darolutamide	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	Metastatic castration-sensitive prostate cancer	Reimburse with clinical criteria and/or conditions	Complete	Jun 16, 2022	Jan 5, 2023	PC0294-000
tebentafusp	Kimmtrak	tebentafusp	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	unresectable or metastatic uveal melanoma	Reimburse with clinical criteria and/or conditions	Complete	Apr 21, 2022	Jan 4, 2023	PC0290-000
edaravone	Radicava	edaravone	Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Rétroaction des intervenants sur la recommandations provisoire	Amyotrophic lateral sclerosis	Reimburse with clinical criteria and/or conditions	Complete	Mar 10, 2022	Dec 22, 2022	SR0727-000

Health Technology Review

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 151 - 175 of 600

Please scroll or swipe to the right to view the full content.

Title	Description	Files	Last Updated Sort ascending	Project Sub Line	Status	Project Number
Midline and Extended Dwell Catheters for IV Antibiotics		Midline and Extended Dwell Catheters for IV Antibiotics	Sep 18, 2023	Rapid Review	Completed	RC1505-000
Non-Sterile Glove Use		Non-Sterile Glove Use	Sep 15, 2023	Rapid Review	Completed	RC1499-000
Somatropin for Short Stature		Somatropin for Short Stature	Sep 15, 2023	Rapid Review	Completed	RC1501-000
Remdesivir (Veklury) for the Treatment of COVID-19 in the Inpatient Setting		Summary Report — September 2023 Systematic Review — September 2023	Sep 13, 2023	Systematic Review	Completed	RE0048-000
Tocilizumab (Actemra) for the Treatment of Hospitalized Patients With COVID-19		Systematic Review — September 2023 Summary Report — September 2023	Sep 13, 2023	Systematic Review	Completed	RE0049-000
Nirmatrelvir-Ritonavir (Paxlovid) for the Treatment of COVID-19		Systematic Review, September 2023 Summary Report, September 2023	Sep 12, 2023	Health Technology Assessment	Completed	HT0042-000
Remdesivir (Veklury) for the Treatment of COVID-19 in the Outpatient Setting		Systematic Review — September 2023 Summary Report — September 2023	Sep 12, 2023	Health Technology Assessment	Completed	HT0041-000
Timing of Ventilator Circuit Tubing Replacement		Timing of Ventilator Circuit Tubing Replacement	Sep 8, 2023	Rapid Review	Completed	RC1498-000
Telephone Triage Services	Telephone triage programs provide timely access to trained health care professionals who can assess a patient’s symptoms over the phone and provide self-care advice or referral to an appropriate level of care.	canadian_telephone_triage_programs_infographic.pdf Telephone Triage Services	Sep 7, 2023	Environmental Scan	Completed	ES0378-000
Prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC)		Implementation Advice	Aug 30, 2023	Technology Review	Completed	HC0060-000
Transcatheter Edge-To-Edge Valve Repair for Tricuspid Regurgitation		Transcatheter Edge-To-Edge Valve Repair for Tricuspid Regurgitation	Aug 22, 2023	Rapid Review	Completed	RC1500-000
Utilization of Opioid Agonist Therapies in Canada		Utilization of Opioid Agonist Therapies in Canada	Aug 15, 2023	Technology Review	Completed	HC0064-000
Lipid Panel Screening for Adults Living With Chronic Conditions		Lipid Panel Screening for Adults Living With Chronic Conditions	Aug 10, 2023	Rapid Review	Completed	RC1497-000
Cost-Effectiveness of an RSVpreF Vaccine for Prevention of Respiratory Syncytial Virus Outcomes in Infants		Cost-Effectiveness of an RSVpreF Vaccine for Prevention of Respiratory Syncytia…	Aug 8, 2023	Technology Review	Complete	HE0044-000
Somatropin for Turner Syndrome		Somatropin for Turner Syndrome	Aug 4, 2023	Rapid Review	Completed	RC1493-000
Somatropin for Growth Hormone Deficiency		Somatropin for Growth Hormone Deficiency	Aug 4, 2023	Rapid Review	Completed	RC1492-000
At-Home Polysomnography Versus In-Clinic Polysomnography for Sleep Disorders		At-Home Polysomnography Versus In-Clinic Polysomnography for Sleep Disorders	Aug 4, 2023	Rapid Review	Completed	RC1495-000
Emergency Care Follow-Up for Children and Adolescents With Suicide Attempts or Ideation		Emergency Care Follow-Up for Children and Adolescents With Suicide Attempts or Ideation	Aug 1, 2023	Rapid Review	Completed	RC1496-000
Evidence Base for Virtual Primary Care		Evidence Base for Virtual Primary Care	Jul 31, 2023	Technology Review	Complete	HC0062-000
Virtual Care Rapid Scoping		Virtual Care Rapid Scoping: Main Report Virtual Care Rapid Scoping: Supporting Information Virtual Care Rapid Scoping: Summary Figures Evidence Map Virtual Care Rapid Scoping: Report Summary	Jul 31, 2023	Scoping Review	Completed	RE0041-000
Individuals’ Access to Medical Imaging Results via Patient Portals		Individuals’ Access to Medical Imaging Results via Patient Portals	Jul 31, 2023	CMII Service	Completed	CM0004-000
Platelet-Rich Plasma Injections for Chronic Tendinopathies in the Upper Extremities		Platelet-Rich Plasma Injections for Chronic Tendinopathies in the Upper Extremities	Jul 31, 2023	Rapid Review	Completed	RC1491-000
Platelet-Rich Plasma Injections for Lower Back Pain		Platelet-Rich Plasma Injections for Lower Back Pain	Jul 31, 2023	Rapid Review	Completed	RC1485-000
Liraglutide for Pediatric Patients with Type 2 Diabetes		Liraglutide for Pediatric Patients with Type 2 Diabetes	Jul 26, 2023	Summary with Critical Appraisal	Completed	RC1494-000
Nirsevimab (Beyfortus) for Respiratory Syncytial Virus Prevention in Neonates and Infants		Nirsevimab (Beyfortus) for Respiratory Syncytial Virus Prevention in Neonates a…	Jul 26, 2023	Technology Review	Complete	HC0059-000

Horizon Scan

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 101 - 110 of 110

Projects in Progress

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 26 - 27 of 27

View All Reports

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 151 - 175 of 2132

Please scroll or swipe to the right to view the full content.

Title	Files	Last Updated Sort ascending	Project Line	Project Sub Line	Status	Project Number
Endometrial cancer		Feb 27, 2025	Reimbursement Review	Provisional Funding Algorithm	Merged	PH0066-000
Urgent Care Centres		Feb 26, 2025	Health Technology Review	Environmental Scan	In Progress	ES0383-000
Subtalar Joint Arthroereisis	Subtalar Joint Arthroereisis	Feb 24, 2025	Health Technology Review	Rapid Review	Completed	RC1568-000
clindamycin plus benzoyl peroxide and adapalene	Recommendation and Reason Patient and Clinician Group input Clinical and Pharmacoeconomic Combined Report Feedback on Draft Recommendation	Feb 21, 2025	Reimbursement Review		Complete	SR0794-000
Multiple Myeloma	Proposed Scope	Feb 20, 2025	Reimbursement Review	Provisional Funding Algorithm	Open for Input	PH0086-000
Breast Cancer	Revised Proposed Scope	Feb 20, 2025	Reimbursement Review	Provisional Funding Algorithm	Active	PH0083-000
zilucoplan	Recommendation and Reason Patient and Clinician Group Input	Feb 20, 2025	Reimbursement Review		Active	SR0838-000
cabozantinib	Proposed Scope	Feb 20, 2025	Reimbursement Review		Active	PX0378-000
sotatercept	Recommendation and Reasons Patient and Clinician Group Input Clinical and Pharmacoeconomic Combined Report Feedback on Draft Recommendation	Feb 19, 2025	Reimbursement Review		Complete	SR0828-000
eplontersen	Recommendation and Reasons Patient and Clinician Group Input Clinical and Pharmacoeconomic Combined Report Feedback on Draft Recommendation	Feb 19, 2025	Reimbursement Review		Complete	SR0826-000
talazoparib		Feb 19, 2025	Reimbursement Review		Withdrawn	PC0316-000
teprotumumab	Patient and Clinician Group Input	Feb 19, 2025	Reimbursement Review		Active	SR0853-001
pertuzumab	Proposed Scope	Feb 14, 2025	Reimbursement Review		Active	PX0379-000
trabectedin	Proposed Scope	Feb 14, 2025	Reimbursement Review		Active	PX0377-000
Melanoma	Proposed Scope	Feb 13, 2025	Reimbursement Review	Provisional Funding Algorithm	Open for Input	PH0072-000
burosumab	Recommendation and Reason Patient and Clinician Group input Clinical and Pharmacoeconomic Combined Report Feedback on Draft Recommendation	Feb 12, 2025	Reimbursement Review		Complete	SR0818-000
Large B cell lymphoma	Final Report	Feb 11, 2025	Reimbursement Review	Provisional Funding Algorithm	Complete	PH0064-000
lebrikizumab	Recommendation and Reason Clinical and Pharmacoeconomic Combined Report Feedback on Draft Recommendation Patient and Clinician Group input	Feb 11, 2025	Reimbursement Review		Complete	SR0819-000
Association Between Opioid Use and the Development of Diverticulitis	Association Between Opioid Use and the Development of Diverticulitis Summary Report Final Project Protocol	Feb 10, 2025	Health Technology Review	Observational Study	Completed	OS0001-000
aflibercept 8mg/0.07mL	Recommendation and Reasons Patient and Clinician Group input Clinical, Pharmacoeconomic and Ethics combined Report Stakeholder feedback on Draft Recommendation	Feb 10, 2025	Reimbursement Review		Complete	SR0813-000
teriflunomide	Recommendation and Reasons Responses to the Questions From the Drug Programs Clinical and Pharmacoeconomic Combined Report Combined Report Supplemental Materials Feedback on Draft Recommendation Patient, Clinician and Industry Input	Feb 10, 2025	Reimbursement Review		Complete	SX0752-000
everolimus	Recommendation and Reasons Responses to the Questions From the Drug Programs Clinical and Pharmacoeconomic Combined Report Stakeholder Feedback on Draft Recommendation Patient, Clinician and Industry Group Input	Feb 10, 2025	Reimbursement Review		Complete	SX0836-000
Mepolizumab	Recommendation and Reasons Responses to the Questions From the Drug Programs Clinical and Pharmacoeconomic Combined Report Patient and Clinician Group Input Feedback on Draft Recommendation	Feb 10, 2025	Reimbursement Review		Complete	SX0839-000
dimethyl fumarate	Recommendation and Reasons Responses to the Questions From the Drug Programs Clinical and Pharmacoeconomic Combined Report Combined Report Supplemental Materials Feedback on Draft Recommendation Patient, Clinician and Industry Input	Feb 10, 2025	Reimbursement Review		Complete	SX0751-000
blinatumomab	Recommendation and Reasons Responses to the Questions From the Drug Programs Clinical and Pharmacoeconomic Combined Report Combined Report Supplemental Materials Patient, Clinician and Industry Input Feedback on Draft Recommendation	Feb 10, 2025	Reimbursement Review		Complete	PX0367-000